10-K: Advanced Biomed Reports Deepening Losses, Nasdaq Compliance Woes

Advanced Biomed Inc. reported significant net losses and negative operating cash flows for fiscal year 2025, alongside a Nasdaq minimum bid price non-compliance notice, while advancing product development and global expansion plans.

Summary

• Advanced Biomed Inc. (ADVB) is a Nevada-incorporated holding company focused on oncology detection solutions through its subsidiaries in Taiwan and Hong Kong.
• The company develops microfluidic technology for early cancer screening, diagnosis, and treatment, utilizing semiconductor and biotechnology.
• Key products include A+Pre, AC-1000, A+CellScan, A+SCDrop devices, and corresponding microfluidic biochips, as well as immunostaining kits and the A+LCGuard Lung Cancer Early Screening Kit.
• A+Pre and AC-1000 devices and their chips have received NMPA clearance in China.
• A+SCDrop, A+CellScan, A+CellScan Chip, and A+LCGuard are at the registration application stage with the NMPA, while four immunostaining kits are under NMPA registration review.
• A+LCGuard, a Class III medical device, requires clinical trials, with clinical research planned to begin in November 2025 and anticipated completion within six months.
• The company reported a net loss of $3,258,969 for the year ended June 30, 2025, an increase from $2,782,278 in 2024.
• Net cash outflow from operating activities was $5,825,055 in 2025, up from $2,126,340 in 2024.
• Working capital surplus increased to $3,143,443 in 2025 from $318,650 in 2024, partly due to related party debt waivers and IPO proceeds.
• Received a Nasdaq notification on July 18, 2025, for non-compliance with the minimum bid price requirement ($1.00 per share) and has until January 14, 2026, to regain compliance.
• Filed a registration statement on Form S-1 on July 23, 2025, to register up to 40,000,000 shares of common stock available under an Equity Line of Credit (ELOC) Agreement.
• Entered into an ELOC Agreement on June 6, 2025, with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. to sell up to $25,000,000 of common stock.
• Plans for global expansion include establishing operation centers in North America (California and Washington) and Europe, with US site selection and personnel recruitment aimed for end of December 2025, and European market entry in 2025 for IVD product registration.
• The company has not commenced sales or generated revenue from products and expects continuous losses for the next two to three years.
• Internal control over financial reporting was deemed ineffective as of June 30, 2025, due to insufficient finance/accounting personnel and lack of proper approval mechanisms.

Sentiment

Score: 3

Explanation: The company is in an early stage with significant R&D progress and strategic expansion plans, but faces substantial financial losses, negative cash flow, Nasdaq compliance issues, and internal control weaknesses, indicating high risk and uncertainty.

Positives

• A+Pre and AC-1000 devices and their corresponding chips have received NMPA clearance in China, indicating regulatory progress for core products.
• The company possesses strong R&D capabilities with a proprietary microfluidic technology platform and ultra-sensitive biosensor technology, enabling rapid product development and cost reduction.
• Pre-mass production trial tests for A+Pre Chips and AC-1000 Enrichment Chips exceeded target recovery rates (94% vs. 90% for A+Pre, 79.5% vs. 75% for AC-1000), demonstrating product efficacy.
• The A+LCGuard lung cancer early screening kit achieved high sensitivity (96%) and specificity (99.9%) in a 123-case scientific research project, providing a strong R&D basis.
• Strategic plans for global expansion into North American and European markets indicate a long-term growth vision and potential for broader market reach.
• Secured an Equity Line of Credit (ELOC) for up to $25,000,000, providing a potential source of future funding to support operations and development.
• The waiver of $2,820,624 in related party debt as of June 30, 2024, significantly improved the company's working capital position.
• Successfully completed an Initial Public Offering (IPO) in March 2025, raising $6.56 million in gross proceeds, enhancing capital resources.

Negatives

• Incurred significant net losses of $3,258,969 for FY2025, an increase from $2,782,278 in FY2024.
• Experienced substantial negative cash flow from operating activities, totaling $5,825,055 in FY2025, a significant increase from $2,126,340 in FY2024.
• The auditor's report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.
• Received a Nasdaq notification on July 18, 2025, for non-compliance with the minimum bid price requirement ($1.00 per share), risking delisting if not resolved by January 14, 2026.
• Has not commenced sales of any revenue-generating products and does not expect to do so until clinical development and regulatory approvals are complete.
• Expects to be in a state of continuous loss for the next two to three years.
• Management concluded that internal control over financial reporting was ineffective as of June 30, 2025, due to insufficient finance/accounting personnel and lack of proper approval mechanisms.
• Possesses relatively limited experience in product promotion and sales, which could hinder commercialization efforts.
• Uncertainty exists regarding market acceptance and reimbursement coverage for products, particularly within China's National Medical Insurance Program.

Risks

• Failure to develop or commercialize early cancer detection devices, chips, or kits on time or at all, and inability to remain competitive.
• Regulatory approvals may be delayed, limited, or never obtained, significantly impairing revenue generation.
• Disruptions at production sites, regulatory compliance issues, or cybersecurity breaches could delay commercialization, raise costs, or harm reputation.
• Inability to obtain and maintain intellectual property protection for products.
• Estimates of expenses, future revenue, capital requirements, and ability to obtain additional financing may be inaccurate.
• Product candidates may fail to demonstrate clinical utility or produce negative/inconclusive results in trials, potentially leading to abandonment of development programs.
• Third-party clinical investigators, medical institutions, or CROs may fail to comply with obligations or meet deadlines, leading to trial delays or termination.
• Failure to keep up with rapid industry and technology developments, rendering proprietary technologies or existing products obsolete.
• Products or services may not perform as expected, leading to negative perception, claims, or service termination.
• Vulnerability to natural disasters, health epidemics (e.g., COVID-19), civil and social disruption, which could significantly disrupt operations.
• Intense competition from companies with longer operating histories, larger customer bases, more expansive brand recognition, and greater resources.
• Failure to attract and retain senior management and other key employees.
• Difficulties in recruiting subjects for clinical trials, leading to delays or adverse effects on development.
• Uncertainties and changes in China's regulations on the cancer screening industry, and the lack of necessary approvals, licenses, registrations, or filings.
• Reliance on third parties for manufacturing, supply, and registration applications, with risks of limitations, interruptions, or unsatisfactory quality/quantity.
• Delays in completing and obtaining regulatory approvals for manufacturing facilities, or damage, destruction, or interruption of production at such facilities.
• Security threats to information technology infrastructure and unauthorized use of data by third parties could expose the company to liability or damage its reputation and business.
• Intellectual property infringement or misappropriation claims by third parties, potentially leading to substantial legal expenses, business disruption, or damages.
• Litigation and other claims and legal proceedings, with unpredictable outcomes and potential for substantial costs and diversion of management attention.
• Inability to generate sufficient operating cash flows and working capital to continue as a going concern, necessitating additional capital which may not be available on acceptable terms.
• Dilution of shareholdings by existing stockholders if additional equity securities are issued in future financing transactions.
• Limited accounting personnel and past error in applying accounting principles for business combinations, indicating potential for future financial reporting issues.
• Economic and political risks associated with doing business in Taiwan, particularly due to geopolitical tension between Taiwan and China.
• Restrictions on Advanced Biomed Taiwan paying dividends or making other payments to the parent company, affecting liquidity.
• Taiwanese foreign exchange controls affecting the ability to repatriate interest, dividends, or sale proceeds.
• Taiwanese laws and regulations on loans to and direct investment in Taiwan entities by offshore holding companies may delay or prevent funding of Advanced Biomed Taiwan.
• Taiwanese regulations on investment or technical cooperation in China may affect Advanced Biomed Taiwan's collaboration with its Shanghai subsidiary.
• A downturn in China or global economy, and economic and political policies of the PRC could materially and adversely affect business.
• Chinese government intervention or influence on operations in Mainland China or Hong Kong, or increased control over overseas offerings and foreign investment.
• Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit legal protections.
• Difficulties for overseas stockholders and/or regulators to conduct investigations or collect evidence within the PRC.
• Regulation and censorship of information disseminated over the Internet in the PRC may adversely affect business, with potential liability for website content.
• Restrictions on dividend payments from PRC subsidiaries.
• PRC regulations relating to offshore investment activities by PRC residents (SAFE Circular 37) may subject beneficial owners or the Shanghai subsidiary to liability or penalties.
• Enhanced scrutiny over acquisition transactions by PRC tax authorities may negatively impact future acquisitions.
• Nasdaq may apply additional and more stringent criteria for continued listing due to a small Initial Public Offering and large insider holdings.
• The market price of common stock may be volatile or decline regardless of operating performance, and stockholders may not be able to resell shares.
• Uncertainty regarding the actual number of shares to be sold under the ELOC Agreement, the actual gross proceeds, and the dilution to existing shareholders.
• Future resales and/or issuances of shares of common stock, or the perception of such sales, may cause the market price to drop significantly.
• Proceeds from sales of common stock under the ELOC Agreement may be used in ways that do not yield a significant return or with which investors may not agree.

Future Outlook

The company expects to be in a state of continuous loss for the next two to three years as it has not commenced sales of revenue-generating products. It plans to initiate clinical research for A+LCGuard in November 2025, with completion anticipated within six months, and aims to obtain the registration certificate by October 2027. Global expansion into North American and European markets is planned for 2025-2026, including localized production and product registration.

Management Comments

• Clinical research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale clinical trials.
• Clinical trials enable an understanding of subject recruitment, facilitate the development of appropriate inclusion and exclusion criteria for later stages, and help verify trial procedures.
• It increases familiarity with the trial products.
• The results of the clinical research will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient statistical power due to a sample size that is too small.
• We recognize that the clinical research results may differ from expectations and may not support our expected progression to clinical trials.
• We expect to be in a state of continuous loss for the next two to three years.
• We intend to monitor the closing bid price of our common stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within the Compliance Period.
• Although no services have been provided to customers yet, the application services using our products and devices will be an essential part of our future operations.
• Enhancing and maintaining awareness of our trademarks and sglcell are critical to achieving widespread acceptance of our microfluidic biochip products, gaining trust for our testing devices and attracting customers.
• Our current practice complies with the Labor Contract Law and its amendments.
• Our cash on hand will be sufficient to meet our anticipated working capital requirements and capital expenditures in the ordinary course of business for the next 6 months, but we cannot assure you this will be the case.
• Management has discussed the development and selection of this critical accounting estimate with our board of directors and the board has reviewed the Company's disclosure relating to it in this MD&A.

Industry Context

Advanced Biomed operates in the rapidly evolving and highly competitive cancer early detection and screening market. The industry is characterized by continuous technological and scientific breakthroughs, increasing data, and the constant emergence of new diagnostic methods. The company's microfluidic technology, which uses a pure physical, antigen-independent mechanism for circulating tumor cell (CTC) enrichment, aims to offer advantages over conventional antibody-based methods that can be costly, time-consuming, and limited by antigen expression. The market demands high sensitivity and specificity for early detection, and the company's strategy involves expanding its presence in China, North America, and Europe, navigating diverse regulatory landscapes for medical devices and in-vitro diagnostics (IVD) products.

Comparison to Industry Standards

• Advanced Biomed's A+LCGuard lung cancer early screening kit achieved 96% sensitivity and 99.9% specificity in a 123-case scientific research project, which compares favorably to some industry benchmarks.
• Universal Diagnostics (UDX) liquid biopsy method for early lung cancer detection showed a preliminary sensitivity of 73% and 90% specificity in a study of 37 lung cancer patients and 71 control subjects.
• Beijing Akron Medical Technology Co., Ltd.'s Aifeiming gene methylation detection kit (P)R-fluorescent probe method) has a clinical sensitivity of 86.83%.
• Advanced Biomed's products utilize pure physical mechanisms (antigen-independent) for CTC enrichment, aiming for high viability and detection of CTCs with low or no antigen expression, which is a potential advantage over conventional antibody-labeling methods (e.g., EpCAM) that can cost approximately $1,000 per chip and take up to 12 hours, and may miss certain CTCs.

Management Changes

Corporate Governance

Legal Proceedings

• Not aware of any pending or threatened material legal or administrative proceedings against the company.

Related Party Transactions

• Loans due to major stockholders (Yi Lu, Chen-Yi Lee, Hung To Pau) totaling $172,767 as of June 30, 2025, which are non-trade, unsecured, interest-free, and repayable on demand.
• Loans due to related corporations (Well Fancy Development Ltd, Shanghai Junfu Electronic Technology Co., Ltd.) totaling $916,036 (current) and $139,772 (non-current) as of June 30, 2025, which are non-trade, unsecured, interest-free, and repayable on demand or over one year.
• Waiver of $2,820,624 in debt owed to certain related parties as of June 30, 2024, which was done to improve the company's working capital.

Stakeholder Impact

• Shareholders face potential for significant dilution from the ELOC agreement and future capital raises, as well as the risk of delisting from Nasdaq due to bid price non-compliance. Continued losses and negative cash flow negatively impact investment value, and Nevada law may limit rights to challenge director actions.
• Employees, particularly R&D personnel, are crucial for technological development, but a workforce shortage in Taiwan could increase operating costs. Non-compete provisions in labor contracts are in place.
• Customers could benefit from advanced, rapid, and affordable cancer detection products, but delays in regulatory approvals could impact product availability and market entry.
• Suppliers are critical as the company relies on third-party manufacturers and suppliers for products and components, introducing supply chain risks.
• Creditors, including related parties, have provided financial support through loans and debt waivers, indicating their importance to the company's liquidity.

Next Steps

• Monitor the closing bid price of common stock and consider all available options to regain Nasdaq compliance by January 14, 2026.
• Initiate the trial stage of A+LCGuard clinical research in November 2025, with completion anticipated within six months.
• Formulate a work plan for large-scale clinical trials for A+LCGuard based on clinical research results.
• Submit A+CellScan and A+CellScan Chips registrations to the NMPA (expected December 2024, but mentioned as ongoing/future in the report's context).
• Complete preliminary works for A+SCDrop's NMPA application.
• Establish operation centers in North America (California and Washington) and Europe.
• Complete US site selection and personnel recruitment by end of December 2025.
• Start product registration, testing, and production in the US afterward.
• Break into the European market in 2025 and start localized registration of IVD products in Europe.
• Implement measures to remedy material weaknesses in internal control over financial reporting, including hiring experienced staff and optimizing financial systems.
• Officially roll out CTC identification and counting service once in-house developed staining reagents complete NMPA registration.

Key Dates

Recommendation

The company exhibits severe financial distress, marked by increasing net losses ($3.3M in FY2025), substantial negative operating cash flow ($5.8M in FY2025), and an explicit expectation of continuous losses for the next 2-3 years. The auditor's report highlights 'substantial doubt about the Company’s ability to continue as a going concern,' which is a critical red flag. Furthermore, the Nasdaq minimum bid price non-compliance notice poses an immediate delisting risk. While the company has promising R&D and global expansion plans, the lack of revenue-generating products, coupled with identified material weaknesses in internal controls, indicates profound operational and financial instability. The ELOC agreement offers potential capital but also significant dilution risk. Given these cumulative factors, the investment is highly speculative with significant downside risk, warranting a strong sell recommendation.

Keywords

Oncology Detection, Cancer Screening, Microfluidic Technology, Circulating Tumor Cells, CTC, Liquid Biopsy, Medical Devices, IVD, NMPA Approval, Clinical Trials, Biotechnology, Semiconductor Technology, Nasdaq Listing, SEC Filing, Financial Losses, Capital Raise, ADVB, Taiwan, China, Healthcare, Diagnostics, Corporate Governance, Internal Controls